New Antibody therapy to fight Cancer

Robert Brooke, CEO of Genesis Biopharma, talks with Joyce about their new antibody therapy, recently approved by the European Patent Office for use as a therapeutic treatment in multiple cancers. Genesis Biopharma is developing its anti-CD55 antibody therapy to neutralize a key cancer defense mechanism that has been found to be over-expressed in more than 80% of solid tumors. The therapy could provide a safe alternative to toxic chemotherapy regimens. The company is initially addressing metastatic colorectal cancer and lymphoma and will be setting up trials to determine its effectivness with other cancers as well.